Susquehanna International Group, LLP Inozyme Pharma, Inc. Transaction History

Susquehanna International Group, LLP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 15, 2024	SELL	$4.33 - $7.31 $69,453 - $117,252	-16,040 Reduced 53.19%	14,114 $62,000
Q1 2024 May 07, 2024	SELL	$4.14 - $7.66 $55,902 - $103,432	-13,503 Reduced 30.93%	30,154 $230,000
Q4 2023 Feb 14, 2024	BUY	$2.71 - $4.5 $118,310 - $196,456	43,657 New	43,657 $185,000
Q2 2023 Aug 11, 2023	BUY	$4.93 - $6.74 $80,871 - $110,562	16,404 New	16,404 $91,000
Q2 2021 Aug 11, 2021	SELL	$15.19 - $21.2 $259,612 - $362,329	-17,091 Closed	0 $0
Q1 2021 May 17, 2021	BUY	$17.77 - $27.9 $303,707 - $476,838	17,091 New	17,091 $338,000
Q4 2020 Feb 16, 2021	SELL	$19.95 - $27.55 $168,956 - $233,320	-8,469 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$17.54 - $30.2 $148,546 - $255,763	8,469 New	8,469 $223,000

53M

3.7K

5.8K

Ticker INZY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,145,700
Market Cap $118M
Description
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.